545 related articles for article (PubMed ID: 35608858)
1. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Based on Start Age and Interval in China: Modeling Study.
Zhao Z; Du L; Li Y; Wang L; Wang Y; Yang Y; Dong H
JMIR Public Health Surveill; 2022 Jul; 8(7):e36425. PubMed ID: 35793127
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
Zhao Z; Gu S; Yang Y; Wu W; Du L; Wang G; Dong H
BMC Cancer; 2024 Jan; 24(1):73. PubMed ID: 38218803
[TBL] [Abstract][Full Text] [Related]
5. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Jaine R; Kvizhinadze G; Nair N; Blakely T
Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
[TBL] [Abstract][Full Text] [Related]
8. Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.
Liu Y; Xu H; Lv L; Wang X; Kang R; Guo X; Wang H; Zheng L; Liu H; Guo L; Chen Q; Liu S; Qiao Y; Zhang S
BMC Med; 2024 Feb; 22(1):73. PubMed ID: 38369461
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.
Zeng X; Zhou Z; Luo X; Liu Q
Front Public Health; 2022; 10():977550. PubMed ID: 36249202
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Lung Cancer Screening in Canada.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness of lung cancer screening worldwide: a systematic review].
Liu CC; Shi JF; Liu GX; Tang W; Zhang X; Li F; Wang L; Ma Y; Su K; Zhao SJ; Gao YB; Li N; Chen WQ; Wu N; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):218-226. PubMed ID: 30744276
[No Abstract] [Full Text] [Related]
13. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.
Behr CM; Oude Wolcherink MJ; IJzerman MJ; Vliegenthart R; Koffijberg H
Pharmacoeconomics; 2023 Apr; 41(4):395-411. PubMed ID: 36670332
[TBL] [Abstract][Full Text] [Related]
14. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
[TBL] [Abstract][Full Text] [Related]
15. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
[TBL] [Abstract][Full Text] [Related]
16. [Priority setting in scaled-up cancer screening in China: an systematic review of economic evaluation evidences].
Shi JF; Mao AY; Bai YN; Liu GX; Liu CC; Wang H; Cao MM; Feng H; Wang L; Bai FZ; Huang HY; Bai HJ; Zhu J; Yan XX; Zhang J; Ren JS; Li N; Dai M; Chen WQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Mar; 54(3):306-313. PubMed ID: 32187937
[No Abstract] [Full Text] [Related]
17. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.
Villanti AC; Jiang Y; Abrams DB; Pyenson BS
PLoS One; 2013; 8(8):e71379. PubMed ID: 23940744
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
Grover H; King W; Bhattarai N; Moloney E; Sharp L; Fuller L
Lung Cancer; 2022 Aug; 170():20-33. PubMed ID: 35700629
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review.
Puggina A; Broumas A; Ricciardi W; Boccia S
Eur J Public Health; 2016 Feb; 26(1):168-75. PubMed ID: 26370440
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
